| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 2.9 | — |
| Net income | 33.6 | -1.8 |
| EPS (diluted, $ a share) | $7.68 | $-1.42 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Operating margin | 70.0% |
|---|
10-Q filed with the SEC, NYSE: APUS. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Apimeds Pharmaceuticals US, Inc.: key numbers
- Share price
- $1.95Close, Nov 17
- Market cap
- $3.6M
- Shares outstanding
- 1.85MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Apimeds Pharmaceuticals US, Inc.
All →Apimeds Pharmaceuticals US Wins Contract from BlockAssure Inc.
Apimeds subsidiary MindWave Innovations entered into a two-year Master Service Agreement with BlockAssure to build, deploy, and operate AssureChain, a dedicated blockchain subnet for insurance and reinsurance operations. MindWave will receive fixed development fees, future maintenance fees, and a 20% allocation of AssureCoin, a digital token to be created by BlockAssure.
- Counterparty
- BlockAssure Inc.
- Term
- 2 years
Apimeds Pharmaceuticals US Leadership Change
Apimeds Pharmaceuticals US, Inc. appointed Eric Sherb as Chief Financial Officer, effective October 1, 2026, succeeding Erick Frim who resigned as Interim CFO. Mr. Sherb, a CPA with 18 years of experience, will receive an annual base salary of $60,000 under his new employment agreement. The company stated that Mr. Frim's resignation was not due to any disagreements regarding operations, policies, or practices.
Apimeds Pharmaceuticals US Wins Contract from AQUAE Holdings Pte. Ltd.
Apimeds Pharmaceuticals' subsidiary MindWave Innovations entered into two 12-month technology services agreements to deploy its MindChain blockchain infrastructure. The first agreement with AQUAE Holdings involves powering AQUAEChain for environmental credit management, while the second with Flash Sports & Media involves creating FlashChain for digital broadcasting rights and video assets.
- Counterparty
- AQUAE Holdings Pte. Ltd. and Flash Sports & Media Holdings, Inc.
- Term
- 12 months
Apimeds Pharmaceuticals US Reverse Stock Split
Apimeds Pharmaceuticals US, Inc. implemented a 1-for-10 reverse stock split of its common stock effective July 24, 2026. The split reduced the number of outstanding shares from approximately 15.1 million to 1.5 million and adjusted the par value to $0.001 per share. The company's common stock began trading on a split-adjusted basis on the NYSE American under the symbol 'APUS' at the market open.